FDA has approved higher doses (3 mg and 4.5 mg) of dulaglutide based on data from the AWARD-11 trial. So what does this mean for the person with diabetes? We now have additional dosing options for dulaglutide which provide greater reduction in hemoglobin A1c and weight. My only potential concern is increased incidence of nausea with these higher doses. These new doses of dulaglutide will be available in pharmacies later this month. For more details, please see the two links below.
Please share your thoughts and subscribe to receive my blogs.
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.